TLDR
- U.S. stock futures tumbled approximately 400 points amid escalating U.S.-Iran geopolitical tensions that sent oil prices surging
- Brent crude approached the $100 per barrel threshold, reigniting concerns over persistent inflation
- Amgen experienced a 5% premarket decline following disappointing trial results from a competitor, weighing on the Dow
- Concerns about additional Federal Reserve interest rate increases resurfaced as the 10-year Treasury yield climbed to 4.81%
- Market participants are closely monitoring Oracle’s upcoming earnings release and Friday’s crucial CPI inflation report
American equity futures experienced significant declines on Tuesday as surging crude oil prices rekindled worries about inflation persistence. Futures tied to the Dow Jones Industrial Average fell approximately 400 points, representing a decline of roughly 0.8%. Futures tracking the S&P 500 declined 0.2%, while Nasdaq 100 futures remained relatively unchanged.

These declines followed an uneventful Monday session, during which financial markets remained shuttered for the Labor Day holiday. While futures contracts traded during a restricted timeframe, regular equity trading did not commence.
Equities had already experienced downward pressure on Friday following a robust employment report that increased the probability of another Federal Reserve rate increase this month. Tuesday’s premarket weakness amplifies that negative momentum.
The primary catalyst was crude oil. Brent crude futures advanced approximately 2.3% to reach nearly $99.20 per barrel. This level represents the closest approach to the $100 mark since July.
The increase followed weekend military exchanges between the United States and Iran. Additionally, Iran announced it was nearing an agreement with Oman to oversee vessel traffic through the Strait of Hormuz, a critical waterway for international petroleum transport.
WTI crude, the domestic U.S. benchmark, was trading near $93 per barrel.
“In a low energy 24 hours the Middle East story has rumbled on as concerns about fresh U.S.-Iran hostilities pushed oil prices higher still,” said Deutsche Bank analyst Jim Reid.
Amgen Drop Adds to Dow Pressure
Amgen shares declined approximately 5% during premarket hours. As one of the thirty components comprising the Dow Jones Industrial Average, its weakness exerted disproportionate downward pressure on the benchmark index.
The selloff occurred after competing pharmaceutical company Novartis disclosed that its late-stage clinical trial evaluating the experimental cardiovascular drug pelacarsen failed to achieve its primary efficacy goal. This development negatively impacted Amgen due to its significant presence in the cardiovascular therapeutics market.
Escalating petroleum prices also drove government bond yields upward. The benchmark 10-year Treasury yield increased 2 basis points to reach 4.81% during early trading hours, reflecting investor expectations for potential additional Federal Reserve monetary tightening.
Market participants are focused on two significant events scheduled for this week. Oracle is slated to release quarterly earnings results later this week, while GameStop reports on Tuesday. Both corporations attract substantial attention from active traders.
On Friday, the Consumer Price Index data release will reveal whether inflationary pressures are moderating toward the Federal Reserve’s 2% objective. An inflation reading exceeding expectations could intensify selling pressure on equities.
The three principal stock indexes declined on Friday after employment data exceeded forecasts, demonstrating robust job creation during August.
As of Tuesday morning, financial markets remain cautious, with crude oil movements, inflation statistics, and Federal Reserve policy expectations dominating investor attention.



